Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Center Eugene Marquis
With
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage III non-small lung cancer;
Patient with at least one of these fragility criteria:
* Status ECOG 1 with multiple comorbidities, at least 2 pathologies with grade ≥ 2 (renal and/or cardiac and/or vascular and/or hepatic, and/or neurologic, and/or pulmonary)
* Status ECOG = 2
* Age \> 74 years
* Age ≥ 70, unfit to receive chemotherapy
Eligible to radiotherapy, defined by multidisciplinary tumor board;
Performance Status Eastern Cooperative Oncology Group (ECOG) 0-2;
Age ≥ 18 years;
Metastasis (M)0 based on clinical, Magnetic Resonance Imaging (MRI) of brain and FluoroDeoxyGlucose (FDG)/ Positron Emission Tomography (PET)- computerized tomography (CT) examinations;
Written informed consent
You may not be if
Patients eligible to surgery
Any prior or current treatment for invasive lung cancer
History of other malignancy within the last 3 years (exception of in situ carcinoma, skin carcinomas, localized prostate carcinoma Gleason 6 and in situ breast carcinoma)
Significant disease which, in the judgment of the investigator, as a result of the medical interview, physical examinations, or screening investigations would make the patient inappropriate for entry into the trial
Known hypersensitivity reaction to nivolumab
Prior organ transplantation including allogenic stem-cell transplantation
Any social, personal, medical and/or psychologic factor(s) that could interfere with the observance of the patient to the protocol and/or the follow-up and/or the signature of the informed consent
